Two JAMA-family publications dropped within three days of each other. On March 10, JAMA Network Open published the first randomized controlled trial to put psilocybin head-to-head against an FDA-approved smoking cessation therapy — nicotine patches — and psilocybin won by a wide margin, with a 6x difference in six-month abstinence rates. On March 13, JAMA published a population study finding Oregon's 2020 decriminalization produced approximately 90,000 additional psilocybin users in the two years that followed — the first empirical measurement of what policy liberalization does to consumption at scale. In the same week, Minnesota's psilocybin therapy bill cleared committee on a bipartisan vote, West Virginia's psilocybin prescription bill passed both chambers and was sent to the governor, and federal legislation to fund psychedelic therapy trials for veterans reached Congress. The policy and science tracks, which have largely operated on parallel timelines, are now converging on the same calendar.

The hardware and platform layer moved in parallel. A randomized controlled trial on bioRxiv — co-authored with contemplative teacher Shinzen Young — showed transcranial focused ultrasound targeting the anterior cingulate cortex accelerates mindfulness progress versus sham, with effect sizes large enough to distinguish active from control conditions. Muse's first EEG-plus-fNIRS consumer headband, the Muse S Athena, received its first extended real-world assessment across 60 sessions. Mindmachines completed its ROSHIwave platform with the first public release of the pROSHI 3. Three distinct hardware signals in one week, spanning clinical-grade research tools to consumer devices, show a category deepening at both ends simultaneously.

Week 11's thesis: psychedelic therapy is crossing from clinical trial evidence to early policy infrastructure, and the companies that will matter are those building the layer above the clinics — training, credentialing, facilitation software, and integration support — not the clinic operations themselves. Numinus Wellness, which tried to own the full stack, disclosed clinic sale, a cease trade order, and TSX delisting risk in the same press release, becoming the second major vertically integrated psychedelic clinic operator to fail after Field Trip. The pattern is now twice confirmed.